LENZ director granted 22,100 stock options

LENZ Therapeutics director Kimberlee C. Drapkin received a stock option grant for 22,100 shares of common stock at an exercise price of $6.63 per share.

Rhea-AI Filing Summary

LENZ Therapeutics director Kimberlee C. Drapkin received a stock option grant for 22,100 shares of common stock at an exercise price of $6.63 per share. The option expires on June 15, 2036 and represents a compensation-related award, not an open-market purchase or sale.

All 22,100 option shares vest in a single installment, provided she continues to serve as an Outside Director. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, she holds 22,100 options directly.

Insider Trade Summary

Grant/Award: 22,100 shares

Grant/Award 1 txn

Insider Drapkin Kimberlee C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,100 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Key Figures

Options granted: 22,100 options Exercise price: $6.63 per share Expiration date: June 15, 2036 +2 more

5 metrics

Options granted 22,100 options Stock option award to director on June 15, 2026

Exercise price $6.63 per share Strike price for 22,100 LENZ common shares

Expiration date June 15, 2036 Option term end date

Total derivative holdings 22,100 options Total shares following transaction reported as options

Cliff vesting date June 15, 2027 Latest possible vesting date, or earlier next annual meeting

Key Terms

Stock Option (right to buy), Outside Director, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Outside Director financial

"Subject to the Reporting Person continuing to be an Outside Director"

exercise price financial

"conversion_or_exercise_price": "6.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-15T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"one hundred percent (100%) of the shares subject to the option shall vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LENZ (LENZ) director Kimberlee C. Drapkin report on this Form 4?

She reported receiving a grant of stock options for 22,100 shares of LENZ common stock at a $6.63 exercise price. This is a compensation award, not an open-market trade, and increases her derivative holdings to 22,100 options.

Is the LENZ (LENZ) Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of stock options, not a market purchase or sale. The transaction code "A" identifies it as an award acquisition, providing the director rights to buy 22,100 shares at $6.63 if the options vest and are exercised.

What are the key terms of Kimberlee Drapkin’s LENZ stock options?

The options cover 22,100 underlying common shares with a $6.63 exercise price and expire on June 15, 2036. All shares vest together if she remains an Outside Director until June 15, 2027 or the next annual stockholder meeting, whichever occurs first.

When do the LENZ (LENZ) director stock options vest according to the filing?

Vesting is cliff-based: 100% of the 22,100 option shares vest on the earlier of June 15, 2027 or the date of the next annual stockholder meeting. Vesting requires she continue serving as an Outside Director through that applicable date under the company’s compensation policy.

How many LENZ shares are covered by the options after this Form 4 grant?

After the reported grant, the director holds options covering 22,100 shares of LENZ common stock. This total comes directly from the "total shares following transaction" figure, indicating her entire reported derivative position from this award in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 08:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drapkin Kimberlee C

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		(1)	06/15/2036	Common Stock	22,100	$0	22,100	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)